thymosin alpha-1 protocol: Frequently asked questions

LL-37 at concentrations above 5 mg per injection volume triggers localized mast cell degranulation in approximately 15% of patients, presenting as erythema and induration within 2–4 hours. Dilute the dose across two injection sites (e.g., 10 mg total split into 5 mg per site) and rotate sites daily. Pre-treating the injection area with ice for 60 seconds reduces mast cell activation without compromising peptide absorption. Persistent inflammation beyond 48 hours may indicate contamination of the reconstituted vial. Discard and prepare a fresh dose.